AstraZeneca Iressa Link To Interstitial Lung Disease Questioned In Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Iressa’s link to interstitial lung disease is uncertain given the similar rate of ILD seen in patients receiving the AstraZeneca drug and placebo, FDA Office of Drug Evaluation I Director Robert Temple, MD, states in a "Feb. 19 review memo.